In people with Graves' disease, certain inflammatory signaling molecules (IL-17a, IL-22, IL-23, and IL-10) tend to increase or decrease together, but their levels do not relate to the levels of autoantibodies that target the thyroid-stimulating hormone receptor.

35

Pro

0

Against

Evidence from Studies

Supporting (1)

35

Community contributions welcome

35

Plasma levels of Th17‐associated cytokines and selenium status in autoimmune thyroid diseases

Cross-Sectional Study

Human

2021 Sep

The study found that certain inflammation-related molecules in Graves' disease patients tend to rise and fall together, which matches the claim. It didn't check the antibody levels, so we can't say for sure if they're linked or not — but that doesn't break the claim.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Plasma levels of Th17‐associated cytokines and selenium status in autoimmune thyroid diseases

Score: 35

DOI: 10.1002/iid3.433

Similar Assertions

In people with Graves' disease, higher levels of two thyroid hormones, FT3 and FT4, are associated with higher levels of certain inflammatory signaling molecules called IL-17a, IL-23, and IL-10, regardless of the levels of autoantibodies present.

35

0

77%

Measurements of five specific immune proteins in the blood are not consistently different between people with Hashimoto’s thyroiditis, Graves’ disease, and people without autoimmune thyroid disease, meaning these proteins cannot be used to tell these conditions apart from each other or from healthy states.

35

0

72%